Dr. Richard D. Carvajal

Dr. Richard D. Carvajal, MD, is a nationally recognized medical oncologist specializing in the treatment of melanoma and rare cancers, including uveal melanoma and other non-cutaneous melanomas. He serves as Deputy Physician-in-Chief and Director of Medical Oncology at the Northwell Health Cancer Institute and is a Professor of Medicine at the Zucker School of Medicine at Hofstra/Northwell. Dr. Carvajal earned his medical degree from New York University School of Medicine and completed his residency in internal medicine at the University of Michigan, followed by a fellowship in medical oncology at Memorial Sloan Kettering Cancer Center. He is board-certified in Internal Medicine and Medical Oncology.

Dr. Carvajal is widely known for his pioneering research in precision oncology and the development of targeted therapies for melanoma and other rare tumors. His clinical and translational research has led to FDA approvals of novel treatments, including therapies for patients with metastatic uveal melanoma. He has served as principal investigator on numerous Phase I–III clinical trials and has authored over 150 peer-reviewed publications. Dr. Carvajal’s work has had a significant impact on the molecular understanding and therapeutic management of melanoma, making him a leading figure in advancing personalized cancer care.

In addition to his research and clinical leadership, Dr. Carvajal is an esteemed educator and active member of national oncology networks. He lectures regularly at international conferences and serves on the editorial boards of top-tier oncology journals. He is a member of professional organizations such as the American Society of Clinical Oncology and the Society for Melanoma Research. Through his commitment to innovation, mentorship, and the advancement of cancer therapeutics, Dr. Carvajal continues to lead transformative efforts in melanoma and rare cancer treatment.